Evaxion Biotech Company Insiders
| EVAX Stock | USD 2.61 0.04 1.56% |
Evaxion Biotech employs about 46 people. The company is managed by 12 executives with a total tenure of roughly 108 years, averaging almost 9.0 years of service per executive, having 3.83 employees per reported executive. Break down of Evaxion Biotech's management performance can provide insight into the company performance.
Evaxion Biotech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Evaxion Biotech's future performance. Based on our forecasts, it is anticipated that Evaxion will maintain a workforce of slightly above 50 employees by August 2025.Evaxion Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.3707) % which means that it has lost $0.3707 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0644) %, meaning that it created substantial loss on money invested by shareholders. Evaxion Biotech's management efficiency ratios could be used to measure how well Evaxion Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 6.72 in 2025, whereas Return On Tangible Assets are likely to drop (0.89) in 2025. At this time, Evaxion Biotech's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 3.5 M in 2025.Common Stock Shares Outstanding is likely to drop to about 3.7 M in 2025. Net Loss is likely to drop to about (23.2 M) in 2025
Evaxion Biotech Workforce Comparison
Evaxion Biotech AS is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 258. Evaxion Biotech retains roughly 46.0 in number of employees claiming about 18% of equities under Health Care industry.
Evaxion Biotech AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Evaxion Biotech AS Price Series Summation is a cross summation of Evaxion Biotech price series and its benchmark/peer.
Evaxion Biotech Notable Stakeholders
An Evaxion Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evaxion Biotech often face trade-offs trying to please all of them. Evaxion Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evaxion Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jesper MSc | Interim COO | Profile | |
| DMSC MD | Chief Officer | Profile | |
| Christian MSc | Chief Officer | Profile | |
| Jrgen EMBA | Head Board | Profile | |
| Bo Karmark | Chief Officer | Profile | |
| Jesper Nissen | Chief Officer | Profile | |
| Thomas Schmidt | Interim Officer | Profile | |
| Per Norlen | Chief Officer | Profile | |
| Thomas MSc | Interim Officer | Profile | |
| Niels MD | VP CoFounder | Profile | |
| Birgitte Rono | Interim Officer | Profile | |
| Andreas Mattsson | CoFounder Officer | Profile |
About Evaxion Biotech Management Performance
The success or failure of an entity such as Evaxion Biotech AS often depends on how effective the management is. Evaxion Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evaxion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evaxion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (1.81) | (1.72) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | 6.40 | 6.72 |
Please note, the imprecision that can be found in Evaxion Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evaxion Biotech AS. Check Evaxion Biotech's Beneish M Score to see the likelihood of Evaxion Biotech's management manipulating its earnings.
Evaxion Biotech Workforce Analysis
Traditionally, organizations such as Evaxion Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evaxion Biotech within its industry.Evaxion Biotech Manpower Efficiency
Return on Evaxion Biotech Manpower
| Revenue Per Employee | 72.7K | |
| Revenue Per Executive | 278.7K | |
| Net Loss Per Employee | 229.3K | |
| Net Loss Per Executive | 879.2K | |
| Working Capital Per Employee | 95.6K | |
| Working Capital Per Executive | 366.4K |
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.